Ty McClure

635 total citations
20 papers, 507 citations indexed

About

Ty McClure is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ty McClure has authored 20 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ty McClure's work include TGF-β signaling in diseases (3 papers), HER2/EGFR in Cancer Research (3 papers) and Renal cell carcinoma treatment (2 papers). Ty McClure is often cited by papers focused on TGF-β signaling in diseases (3 papers), HER2/EGFR in Cancer Research (3 papers) and Renal cell carcinoma treatment (2 papers). Ty McClure collaborates with scholars based in United States, Canada and New Zealand. Ty McClure's co-authors include Matthew L. Sherman, Dawn Wilson, Kenneth M. Attie, Hugh J. McMillan, Diana M. Escolar, Jean K. Mah, Kathryn Selby, Mark A. Tarnopolsky, Craig Campbell and Amelia E. Pearsall and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Ty McClure

20 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ty McClure United States	11	246	103	88	83	81	20	507
Huihui Liu China	12	166 0.7×	87 0.8×	25 0.3×	64 0.8×	45 0.6×	55	562
Garrett Z. Ng Australia	17	180 0.7×	45 0.4×	36 0.4×	72 0.9×	67 0.8×	32	571
Sergey Sikora United States	10	164 0.7×	158 1.5×	21 0.2×	32 0.4×	43 0.5×	12	559
Ji Young Huh South Korea	11	232 0.9×	48 0.5×	30 0.3×	64 0.8×	73 0.9×	26	440
Jette Brandt Denmark	12	140 0.6×	53 0.5×	32 0.4×	115 1.4×	70 0.9×	15	664
Frank Stolz Austria	14	193 0.8×	54 0.5×	210 2.4×	220 2.7×	68 0.8×	30	903
Melanie K. Kuechle United States	11	183 0.7×	69 0.7×	52 0.6×	28 0.3×	61 0.8×	15	725
Victoria G. Aveson United States	9	370 1.5×	37 0.4×	30 0.3×	48 0.6×	107 1.3×	16	776
Ellen Gilkerson United States	12	112 0.5×	47 0.5×	25 0.3×	94 1.1×	51 0.6×	15	525
N Borregaard Denmark	8	272 1.1×	32 0.3×	108 1.2×	79 1.0×	45 0.6×	10	644

Countries citing papers authored by Ty McClure

Since Specialization

Citations

This map shows the geographic impact of Ty McClure's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ty McClure with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ty McClure more than expected).

Fields of papers citing papers by Ty McClure

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ty McClure. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ty McClure. The network helps show where Ty McClure may publish in the future.

Co-authorship network of co-authors of Ty McClure

This figure shows the co-authorship network connecting the top 25 collaborators of Ty McClure. A scholar is included among the top collaborators of Ty McClure based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ty McClure. Ty McClure is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ratziu, Vlad, Mary E. Rinella, Brent Tetri, et al.. (2020). EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study. Journal of Hepatology. 73. S56–S57. 5 indexed citations

Coakley, Eoin, Alaa Ahmad, Kajal Larson, et al.. (2019). LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study. Open Forum Infectious Diseases. 6(Supplement_2). S995–S995. 7 indexed citations

Yap, Timothy A., Howard A. Burris, Shivaani Kummar, et al.. (2018). ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.. Journal of Clinical Oncology. 36(15_suppl). 3000–3000. 28 indexed citations

Harb, Wael A., Alex A. Adjei, M. Beeram, et al.. (2016). Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2518–2518. 1 indexed citations

Sequist, Lecia V., Nathan Demars, Enriqueta Felip, et al.. (2016). A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(15_suppl). TPS9110–TPS9110. 3 indexed citations

Campbell, Craig, Hugh J. McMillan, Jean K. Mah, et al.. (2016). Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial. Muscle & Nerve. 55(4). 458–464. 172 indexed citations

Saleh, MN, Rodolfo Bordoni, Anthony F. Shields, et al.. (2016). A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors. European Journal of Cancer. 69. S137–S138. 5 indexed citations

LoRusso, Patricia, Ian E. Krop, Kathy D. Miller, et al.. (2015). Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer. Cancer Research. 75(15_Supplement). CT234–CT234. 24 indexed citations

Kurzrock, Razelle, Evanthia Galanis, Derek R. Johnson, et al.. (2014). A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer.. Journal of Clinical Oncology. 32(15_suppl). 2092–2092. 10 indexed citations

10.

Attie, Kenneth M., Mark Allison, Ty McClure, et al.. (2014). A phase 1 study of ACE‐536, a regulator of erythroid differentiation, in healthy volunteers. American Journal of Hematology. 89(7). 766–770. 88 indexed citations

11.

Jimeno, Antonio, Marshall R. Posner, Jared Weiss, et al.. (2014). Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology. 32(15_suppl). 6045–6045. 5 indexed citations

12.

Atkins, Michael B., Martin H. Voss, Elizabeth R. Plimack, et al.. (2014). A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.. Journal of Clinical Oncology. 32(15_suppl). 4566–4566. 4 indexed citations

13.

Bendell, Johanna C., Michael S. Gordon, Herbert I. Hurwitz, et al.. (2013). Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer. Clinical Cancer Research. 20(2). 480–489. 47 indexed citations

14.

Atkins, Michael B., Rupal S. Bhatt, Martin H. Voss, et al.. (2013). Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 31(15_suppl). TPS4595–TPS4595. 1 indexed citations

15.

Jimeno, Antonio, Lori J. Wirth, Marshall R. Posner, et al.. (2013). Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology. 31(15_suppl). TPS6098–TPS6098. 1 indexed citations

16.

Dunbar, Lala M., et al.. (2011). Comparison of the Efficacy and Safety of Oritavancin Front-Loaded Dosing Regimens to Daily Dosing: an Analysis of the SIMPLIFI Trial. Antimicrobial Agents and Chemotherapy. 55(7). 3476–3484. 54 indexed citations

17.

McClure, S.J., Ty McClure, & D.L. Emery. (1999). Effects of molybdenum intake on primary infection and subsequent challenge by the nematode parasiteTrichostrongylus colubriformisin weaned Merino lambs. Research in Veterinary Science. 67(1). 17–22. 19 indexed citations

18.

McClure, Ty. (1959). An investigation of the fertility of a random sample of waikato dairy herds. New Zealand Veterinary Journal. 7(2). 31–38. 10 indexed citations

19.

Hartley, W. J., et al.. (1955). Pathology of brucellosis in rams in New Zealand. New Zealand Veterinary Journal. 3(3). 100–104. 13 indexed citations

20.

McClure, Ty, et al.. (1951). Absorption of Anti-Nematode Antibodies from Ewe's Colostrum by the New-born Lamb. Nature. 168(4265). 170–170. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact